Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets
Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection, craniospinal radiation, and chemotherapy. However, many patients do not resp...
Saved in:
Published in | Frontiers in immunology Vol. 14; p. 1062856 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
07.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Medulloblastoma is the most common and lethal pediatric malignant brain tumor. It comprises four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4. Medulloblastoma treatment is surgical resection, craniospinal radiation, and chemotherapy. However, many patients do not respond to therapy, and most suffer severe side effects. Cancer immunotherapy targeting immune checkpoints (IC) (PD-1, PD-L1, and CTLA4) has been getting disappointing outcomes in brain tumors. Nevertheless, other less explored immune checkpoints may be promising candidates for medulloblastoma therapy.
In the present study, we aimed to characterize the expression profile of 19 immune checkpoints in medulloblastoma.
We analyzed 88 formalin-fixed paraffin-embedded medulloblastomas previously classified for each molecular subgroup and three non-tumoral brain tissue. mRNA levels of 19 immune checkpoint-related genes were quantified using the nCounter (PanCancer Immune Profiling Panel) assay. Further
analysis was performed in two larger public microarray datasets, one of which enabled comparisons between tumoral and non-tumoral tissues. Immunohistochemistry of PD-L1 was performed in a subset of cases. Microsatellite instability was also molecularly analyzed.
We observed an absence of expression of the canonic ICs, namely
(PD-1),
(PD-L1), and
, as well as
, and
PD-L1 protein expression was also practically absent. We found higher mRNA levels of
,
(B7-H3), and
, and lower mRNA levels of
,
, and
genes, with significant differences across the four molecular subgroups. Compared to the non-tumor tissues, the expression levels of
in all subgroups and
in SHH, Group 3, and Group 4 subgroups are significantly higher. The
analysis confirmed the expression profile found in the Brazilian cohort, including the lower/absent expression of the canonic ICs. Moreover, it confirmed the overexpression of
and
in medulloblastomas compared with the non-tumor tissue. Additionally,
and CD24 high levels were associated with worse survival.
These results highlight the low or absence of mRNA levels of the canonic targetable ICs in medulloblastomas. Importantly, the analysis revealed overexpression of
and
, which can constitute prognostic biomarkers and attractive immunotherapy targets for medulloblastomas. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Zaoqu Liu, First Affiliated Hospital of Zhengzhou University, China Reviewed by: Yu’e Liu, Tongji University, China; Hehai Pan, University of Pennsylvania, United States; Zhaohua Hou, Memorial Sloan Kettering Cancer Center, United States This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology |
ISSN: | 1664-3224 1664-3224 |
DOI: | 10.3389/fimmu.2023.1062856 |